WuXi Biologics (Cayman) Inc. (HKG:2269)
35.42
-0.92 (-2.53%)
At close: Mar 9, 2026
WuXi Biologics Employees
WuXi Biologics had 12,552 employees as of June 30, 2025. The number of employees decreased by 23 or -0.18% since the number was reported on December 31, 2024.
Employees
12,552
Change
-23
Growth
-0.18%
Revenue / Employee
1.75M HKD
Profits / Employee
366.33K HKD
Market Cap
146.55B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 12,552 | -23 | -0.18% |
| Dec 31, 2024 | 12,575 | -165 | -1.30% |
| Dec 31, 2023 | 12,740 | 367 | 2.97% |
| Dec 31, 2022 | 12,373 | 2,509 | 25.44% |
| Dec 31, 2021 | 9,864 | 3,218 | 48.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 23,056 |
| BeOne Medicines AG | 11,000 |
| 3SBio | 6,268 |
| Innovent Biologics | 6,190 |
| Shanghai Henlius Biotech | 3,537 |
| Akeso | 3,529 |
| RemeGen | 3,070 |
| Shanghai Junshi Biosciences | 2,670 |
WuXi Biologics News
- 7 days ago - WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year - PRNewsWire
- 26 days ago - WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off - South China Morning Post
- 26 days ago - Hong Kong stocks rise as positive holiday bias sets in ahead of Lunar New Year - South China Morning Post
- 4 weeks ago - WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally - PRNewsWire
- 5 weeks ago - WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody - PRNewsWire
- 6 weeks ago - HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline - PRNewsWire
- 7 weeks ago - JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth - PRNewsWire
- 7 weeks ago - WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic - PRNewsWire